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ABSTRACT
Background Postinfectious bronchiolitis obliterans (BO)
is a chronic respiratory disease that usually follows a
severe adenovirus infection.
Objective To determine the evolution of pulmonary
function and clinical outcome of children with
postinfectious BO during childhood.
Methods The study included patients diagnosed with
postinfectious BO in whom at least two spirometries
were performed within a minimum interval of 3 months.
Results 46 met the inclusion criteria. The mean (±SD)
follow-up period was 12.5 (±3.5) years. 197
spirometries and 41 plethysmographies were performed.
Initial (9±3 years old) lung function was as follows
(z score, mean±SD): forced vital capacity (FVC) −3.8±1;
forced expiratory volume in 1 s (FEV1) −4.4±1;
FEV1/FVC −2.2±1; forced expiratory flow (FEF)25–75
−3.7±1; total lung capacity (TLC) 120±26%; residual
volume (RV) 309±108%; and RV/TLC 55±13. During
childhood, FVC and FEV1 increased by a mean of
11%/year (95% CI 9.3% to 12.6%; p<0.0001) and
9%/year (95% CI 7.7% to 10.2%; p<0.0001), and the
FEV1/FVC ratio decreased by 1.9%/year (95% CI 1% to
2.8; p<0.001). The z score for FVC, FEV1 and FEV1/FVC
decreased by 0.07 z score/year (95% CI 0.1 to 0.01;
p<0.05), 0.09 z score/year (95% CI 0.1 to 0.05;
p<0.01) and 0.04 z score/year (95% CI 0.09 to 0.001;
p<0.02), respectively. During the follow-up period, 69%
of patients required at least one hospital readmission
and five required mechanical ventilation. Nine patients
developed a thoracic deformity, and seven whose
bronchiectasis did not respond to clinical treatment
underwent a lobectomy.
Conclusions After a 12 year follow-up period,
pulmonary function remained severely impaired, showing
an obstructive pattern with air trapping that slowly
improved during childhood. An unequal growth of lung
parenchyma over the airways suggests dysinaptic growth.
Patients required frequent readmission due to recurrent
respiratory infections, and hypoxaemia improved slowly
over time.
INTRODUCTION
Bronchiolitis obliterans (BO) is an uncommon
chronic respiratory disease that generally appears
following a severe insult of the lower respiratory
tract. Causes may include complications of graft
versus host disease in bone marrow transplant reci-
pients, chronic graft rejection in lung transplant
recipients and Stevens–Johnson syndrome. In many
parts of the world BO is most commonly seen in
children after severe viral lower respiratory tract
infections.1 Postinfectious BO has been reported
mainly in Argentina,2 Chile,3 Southern Brazil,4 and
Turkey,5 and in native populations in Australia and
Canada;6–8 other areas, such as the USA and
Europe, have reported a small number of patients.9
Reasons for the difference in prevalence of the
disease may include the severity of the adenovirus
infections according to serotype10 11 and a genetic
predisposition to develop the disease.12
We previously reported that adenovirus infection
and mechanical ventilation are significant risk
factors for children developing postinfectious BO.2
Hence when an adenovirus infection is detected
and the patient does not improve, BO should be
suspected.
Postinfectious BO usually occurs in infants
younger than 6 months.2 Initially, these patients
present symptoms that do not differ from severe
bronchiolitis. BO is clinically characterised by tach-
ypnoea, increased anteroposterior chest diameter,
crackles, wheezing and hypoxaemia for at least
30 days after the initial injury.11 13 In addition to
clinical characteristics, infant pulmonary function
Key messages
What is the key question?
▸ Lung function development and the clinical
outcome of patients with postinfectious
bronchiolitis obliterans throughout childhood
remains poorly defined.
What is the bottom line?
▸ In the past decades, indentification of a
growing number of patients that survived a
severe insult of the lower respiratory tract,
usually due to adenovirus infection, allowed us
to perform a prospective cohort study to bring
to light the development of lung function and
clinical aspects of these patients.
Why read on?
▸ This large prospective study is the first to
systematically examine lung function and
clinical outcome of postinfectious bronchiolitis
obliterans patients over a follow-up period of
more than 12 years.
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(PF) shows a severe and fixed airway obstruction, and high reso-
lution chest CT scan shows characteristic mosaic patterns and
bronchiectasis.13 14 During hospital admission, most patients are
found to have severe airway obstruction with hypoxaemia, and
in many cases mechanical ventilation is required.
We have published a BO score. The BO score is a simple to
use clinical prediction rule, based on elements that are readily
available in most medical centres, and is used widely in our
country.15 The score is made up of three variables: typical clin-
ical history of postinfectious BO with hypoxaemia (defined as a
previously healthy infant, with a severe episode of bronchiolitis
and resultant chronic respiratory hypoxaemia for more than
60 days (O2 sat <92%), at rest over 15 min and breathing room
air); history of adenovirus infection; and high resolution CT
scan with mosaic pattern. The presence of two of these three
variables makes a BO score of 7 or more, predicting a diagnosis
of postinfectious BO with high accuracy.
Our current knowledge about the outcome of patients with
postinfectious BO is based largely on a few series of cases with a
short follow-up.3 6 In 1996, in the Respiratory Centre of the R
Gutierrez Children’s Hospital, Buenos Aires, Argentina, we
began a prospective cohort observational and descriptive study
of patients with postinfectious BO.
The objective of this study was to determine the evolution of
PF and clinical outcome of children with postinfectious BO
during childhood.
METHODS
The study included patients diagnosed with postinfectious BO
between 1996 and 2012 in the Respiratory Centre of R
Gutierrez Children’s Hospital, Buenos Aires, Argentina, in
whom at least two spirometries were performed with a
minimum interval between them of >3 months.
The diagnosis of postinfectious BO was based on a positive
BO score as well as a high resolution CT scan compatible with
BO, and PF with a severe and fixed obstructive pattern.15
Children with cystic fibrosis, congenital heart disease, primary
ciliary dyskinesia or immunodeficiencies were excluded. The BO
score was calculated by assigning points to the following vari-
ables: typical clinical history (4 points), adenovirus infection (3
points) and high resolution CTwith mosaic perfusion (4 points).
A score of 7 predicts BO diagnosis with a specificity of 100%
(95% CI 79% to 100%) and a sensitivity of 67% (95% CI 47%
to 80%).15
Ricardo Gutierrez Children’s Hospital is a tertiary care centre
associated with Buenos Aires University that receives referrals
from all over the country. Ethics approval was granted by local
ethics committee.
Based on the national consensus, patients received home
oxygen therapy when SpaO was <93%. Clinical outcome was
assessed during follow-up visits, which included physical exam-
ination, anthropometry, pulse oximetry, radiological images and
PF tests. During these visits, patients were evaluated by a pulmo-
nologist, cardiologist, nutritionist and caseworker. After dis-
charge from the hospital, visits were planned every 2 weeks, and
once they became clinically stable, visits were arranged at least
three times a year. The frequency of the follow-up visits was
scheduled according to the clinical status of the patient.
PF tests included spirometry and plethysmography. A broncho-
dilator response to 200 μg of albuterol administered by MDI
through a volume spacer device with mouthpiece (Aerochamber)
was evaluated according to the American Thoracic Society
recommendations. PF was evaluated with standardised techni-
ques using a Vmax series 2, Sensormedics. PF tests were obtained
when the patient’s condition was stable (absence of an acute
respiratory tract infection for the last 30 days and no upper
airway secretions). The reference equations used to calculate
their SD scores were performed according to the global lung
function 2012 equations.16
Statistical analysis
Longitudinal panel data analysis was used to assess the change
in PF tests over time. Longitudinal data were analysed using
generalised linear mixed effects models, as implemented in R
(lme4 library), with random effects specified at the level of the
individual. Normal distribution of dependent variables was eval-
uated using the Shapiro–Wilks test; variables not normally dis-
tributed were log transformed before analysis and log normality
confirmed with the Shapiro–Wilks test for the transformed vari-
ables. CIs (95% CI) for generalised linear mixed effects regres-
sions were estimated by Markov Chain Monte Carlo methods,
as implemented in WinBUGS and R.17
All increases and decreases in PF test values are described as
changes in z score for height. Data were analysed using R soft-
ware 2.10.0 version (26 October 2009) (The R Foundation for
Statistical Computing ISBN 3-900051-07-0) and WinBUGS.
Statistical significance was assumed at p<0.05 or the 95% CIs
that did not include the null value (1.0), as applicable. All
p values are uncorrected.
RESULTS
Among a cohort of 155 patients with a diagnosis of postinfec-
tious BO, 46 met the inclusion criteria. In 55% of these patients
an adenovirus had been detected (table 1).
The first PF test in each patient was obtained at the time when
they were able to perform the manoeuvre, at an average age of 9
±3 years old. These showed a severe obstructive pattern with air
trapping that did not respond to bronchodilators (table 2).
Pulmonary function
Lung function in our cohort was followed for an average of
12.5±3.5 years. Overall, 196 spirometries were performed; the
number of studies was different for each patient, with an
average of 4.4±2.3 spirometries per patient (table 2).
As patients grew up, from 5 to 20 years of age, we observed
an increase in forced vital capacity (FVC) and forced expiratory
volume in 1 s (FEV1) and a decrease in the Tiffenau index. FVC
and FEV1 increased by a mean of 11%/year (95% CI 9.3% to
12.6%; p<0.0001) and 9% /year (95% CI 7.7% to 10.2%;
p<0.0001), respectively, and the FEV1/FVC ratio decreased by




Age at diagnosis (months)* 14±3
CT scan with mosaic perfusion (%) 56
Adenovirus infectious detected (%) 55
Age (years) at initial lung function* 9.5±3
Duration of follow-up (years)* 12.5±3.5
No of spirometries 196
Spirometries per patient* 4.4±2.3
Z score BMI* −0.5±1.3
*Mean±SD.
BMI, body mass index.
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1.9% per year (95% CI 1% to 2.8%) (figure 1; see online sup-
plementary table 3 and figure 6). Therefore, a disproportionate
increase in FVC compared with FEV1 was observed.
The strongest association between the evolution of spiro-
metric parameters and growth was observed when they were
related to the development of height (figure 1). FVC and FEV1
increased by a mean of 2.3%/cm of height gained (95% CI
2.1% to 2.6%; p<0.0001) and 1.8%/cm of height gained (95%
CI 1.6% to 2.0%; p<0.0001), respectively, and the FEV1/FVC
ratio decreased by 0.4%/cm of height gained (95% CI 0.2% to
0.6%; p<0.001) (see online supplementary table 3).
When spirometric parameters were expressed as z scores, they
decreased during growth, showing that the growth of PF in BO
patients lags behind that of healthy children. The z scores for
FVC, FEV1 and of the Tiffenau index decreased by 0.07 z
score/year (95% CI 0.1 to 0.01; p<0.05), 0.09 z score/year
(95% CI 0.1 to 0.05; p<0.01) and 0.04 z score/year (95% CI
0.09 to 0.001; p<0.02), respectively (figure 2; online supple-
mentary table 4 and figure 7).
Twenty-eight patients underwent 44 plethysmographies.
Initial plethysmography was performed at a mean age of 11
±3.3 years and the results were: total lung capacity (TLC) 120
±26%, residual volume (RV) 309±108% and RV/TLC 55±13.
The response to albuterol was highly variable; on average it
decreased by 4.5±44% and 3.31±26% for RV and TLC,
respectively.
An annual decrease was observed in TLC and RV of 12±4%
and 12±11.6%/year, respectively, in those patients (27 patients)
for whom results for more than one plethysmographic study
were available.
Clinical outcome
At the initial assessment of lung function (9.5±3.3 years),
patients had a z score for height (mean±SD) −1.1±−1.1,
weight 1.48±0.9, relationship of weight/height −0.2±0.7 and a
body mass index z score of −0.5±1.3. At the end of the moni-
toring period (20 years old), these parameters had not changed
significantly (height z score −0.96±0.85, weight z score weight
and body mass index z score −0.41±1.7).
Most patients (84%) required oxygen supplementation for a
median of 5 months (IQR 2–26 months) after discharge from
the initial hospital admission. Oxygen saturation improved
slowly over several years, and only one patient continued to
need supplemental oxygen at age 10 years (figure 3). During the
Figure 1 Relationship between pulmonary function tests and the development of height. Longitudinal data analysed using generalised linear
mixed effects models. Population regression (red line) and 95% CI (shaded area). Individual data are depicted by black lines. (A) Forced vital
capacity (FVC) versus height. Regression performed on log transformed FVC. (B) Forced expiratory volume in 1 s (FEV1) versus height. Regression
performed on log transformed FEV1. (C) FEV1/FVC ratio versus height.
Table 2 Initial lung function of patients with postinfectious
bronchiolitis obliterans
Variable Values
FVC (z score) −3.8±1
FEV1 (z score) −4.3±1
FEV1/FVC (z score) −2.2±1




Values are expressed as mean±SD.
FEF, forced expiratory flow; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; RV, residual volume; TLC, total lung capacity.
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follow-up period, 69% of patients required at least one readmis-
sion, which diminished over the years (during the first 2 years
the mean number of readmissions was 1.6, with 0.12 admission/
year/patient thereafter).
Readmissions were mainly due to respiratory infections (96%)
requiring in all cases treatment with antibiotics, bronchodilators
and physiotherapy. Five patients required mechanical ventilation
during a readmission and one patient died. After 6 years of age,
patients showed chest radiographs with air trapping (100%),
atelectasis (71%), areas with an increased interstitial pattern
(62%) and honeycombing (46%). The most frequent findings
on high resolution CT scans were bronchiectasis (78%) and
mosaic perfusion (56%).
Nine patients developed a thoracic deformity, consisting of an
asymmetric pectus carinatum. Three underwent corrective
surgery (figure 4). Seven patients whose bronchiectasis did not
respond to clinical treatment underwent surgery—six had lobec-
tomies (one or two lobes) and one had a left pneumonectomy.
The most commonly affected lobes were middle lobe
(3 patients), right upper lobe (3 patients), left lower lobe
(1 patient) and right inferior lobe (1 patient) (figure 5). After
surgery, none of the patients required ventilator support but
complications were frequent (56%, three wound infections, two
pneumothorax and two bronchopleural fistulas).
DISCUSSION
In this study, among children with postinfectious BO, after more
than a 12 year follow-up period, patients showed severely
impaired PF with an obstructive pattern with severe air trapping
(table 2) that improved slowly with growth (figure 1).
Hypoxaemia also improved over time (figure 3) but patients
required frequent readmission to hospital because of recurrent
respiratory infections.
Although a mixed pattern has been described by other
authors,9 in the present study all patients had a pattern of PF
characterised by obstruction of the medium to small airways
with consequent air trapping, as indicated by an increased RV%
and RV/TLC ratio (table 2).
Figure 2 Relationship between pulmonary function, expressed as z score, and the development of height. Longitudinal data analysed using
generalised linear mixed effects models. Population regression (red line) and 95% CI (shaded area). Individual data are depicted by black lines. (A) Z
score for forced vital capacity (FVC) (expressed as SD from the mean FVC for height) versus height. (B) Z score for forced expiratory volume in 1 s
(FEV1) (expressed as SD from the mean FEV1 for height) versus height. (C) Z score for FEV1/FVC ratio (expressed as SD from the mean FEV1/FVC ratio
for height) versus height.
Figure 3 Percentage of patients who received supplementary oxygen
from the time of discharge from the initial hospital admission until they
were 10 years of age.
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The obstructive lung disease seen in our study was as
expected, but conflicting results have been reported regarding
its progression in childhood. A previous study, including only
11 patients with postinfectious BO, reported that PF declined
with growth.19 In our patients, however, although the z scores
for FVC and FEV1 decreased (figure 2), values for FVC and
FEV1 increased at the same time as they grew up from 5 to
20 years of age (figure 1), showing that the development of lung
function in BO patients is slower or lower than in healthy chil-
dren. Ethnicity, and genetic and social factors may contribute to
these differences, as the prevalence of the disease in South
America is one of the highest reported. The fact that FVC
increased more than FEV1 could be explained by an unequal
growth of lung parenchyma and airways, indicative of a ‘dysy-
naptic growth’ of the lung (figure 1). The most likely explan-
ation for this lung growth may be the concept of the
neoalveolisation throughout childhood and adolescence postu-
lated by Narayanan et al. However, this catch-up growth after
the lung injury could be possible in terms of alveolar number,
but may be not as much for airway size.20 21
Similar to healthy children, the strongest association between
the development of lung function values and growth in BO
patients was observed when they were associated with the devel-
opment of height (figure 1).
While the mean bronchodilator response in FEV1 was nearly
12%, RV diminished by less than 200 mL.22 Patients with a sig-
nificant bronchodilator response (>12% in FEV1 and >200 mL
in RV) were few but are important to identify because in these
patients bronchodilators can help improve lung function.
Although spirometric parameter values increased, PF remained
severely impaired in childhood. In the same way, plethysmo-
graphic studies showed a decrease in air trapping.
Quality of life, to the extent that patients no longer needed
supplemental oxygen and had less hospital readmissions, was at
least in part the result of the development of PF (figure 3).
Unlike other studies that reported remission of the pulmonary
sequelae,3 4 we did not observe remissions in our patients, pos-
sibly because we included a homogeneous group of patients
with severe lung damage (table 2) while other studies may have
included patients with milder forms of the disease.
In childhood, 6 years after the beginning of the disease, our
cohort of BO patients showed a suitable nutritional status. This
condition may be the result of the balance between a high nutri-
tional input and high nutritional requirements due to the
increased respiratory work; furthermore, some patients with a
very low income (due to socioeconomic conditions) showed
important nutritional deficiencies.
Enhancing overall growth should be one of the main objec-
tives in the treatment of these patients, because even with irrep-
arable lung damage, physical maturation is the key to the
development of the lung and the last chance to improve lung
function and quality of life.
An interesting observation was the development of thoracic
deformities following postinfectious BO (figure 4); other dis-
eases such as bronchopulmonary dysplasia,23 24 severe asthma25
and congenital heart disease have also been reported to cause
thoracic deformities.26 Three of our patients with thoracic
deformities underwent corrective surgery and did not develop
post surgical complications. We speculate that the abnormalities
resulted from a combination of demineralised bones and
chronic air trapping. It is plausible that these chest wall deform-
ities may be clinically deleterious due to interference with
respiratory mechanics.18
The main treatment objective is tailored control for each
patient according to lung damage and clinical response. Some
patients required more courses of antibiotics and chest physio-
therapy because of bronchiectasis (figure 5), and a few
patients had a significant response to bronchodilators. In spite
of the various treatments, lung damage was irreversible. Other
studies have suggested a potential role for maintenance
Figure 4 Radiological images and thoracic deformity of a patient with postinfectious bronchiolitis obliterans at 11 years of age.
Figure 5 CT scan of patients with
postinfectious bronchiolitis obliterans
showing bronchiectasis. Left: patient
with total collapse of the right lung
with bronchiectasis. Note the
hyperinsuflation of the left lung. Right:
patient with bronchiectasis in the right
and left lower lobes.
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macrolide therapy in BO following bone marrow or lung
transplantation;27–29 another study described successful treat-
ment of BO in a bone marrow transplant patient with tumour
necrosis factor α blockade (Infliximab).30 We have not evalu-
ated the potential benefits of these treatments in postinfec-
tious BO.
An important decision in the treatment of patients with post-
infectious BO is whether to perform a lobectomy as PF is
severely impaired and most patients develop complications after
surgery. In patients who have bronchiectasis localised primarily
to one lobe and in whom clinical treatment has failed, reducing
quality of life, surgery may be a useful alternative.
Important factors to consider in future research include the
ideal timing, dosage and best choice of immunosuppressive
agents to avoid BO development. Clinical trials of potential
therapeutic agents should be multicentric in order to include a
significant number of patients.
We conclude that after a 12 year follow-up period, PF
remained severely impaired, showing an obstructive pattern
with air trapping that slowly improved during childhood. This
improvement may be mainly due to the development of lung
parenchyma more than airway growth. Patients required fre-
quent readmission to hospital due to recurrent respiratory infec-
tions, and hypoxaemia improved slowly over time.
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